Delaying Infant Hepatitis B Vaccination Increases Infections and Costs

The Clinical Stakes of Early Life Hepatitis B Immunization

Hepatitis B virus remains a significant driver of global morbidity, contributing to a substantial portion of the nearly 600,000 annual deaths from liver cancer worldwide [1, 2]. While universal infant vaccination is a cornerstone of elimination efforts, mother-to-child transmission continues to pose a serious public health challenge, with transmission rates reaching as high as 31.3 percent in the absence of prophylaxis [3]. Current clinical guidelines emphasize the importance of triple panel testing (a screening process involving hepatitis B surface antigen, antibody to surface antigen, and total antibody to core antigen) during pregnancy to identify at-risk neonates and ensure timely immunoprophylaxis [2]. However, the implementation of birth-dose protocols varies globally, and the clinical impact of altering these schedules remains a subject of intense debate [4, 5]. Prompted by a 2025 Advisory Committee on Immunization Practices recommendation to delay vaccine initiation for certain infants, a new analysis evaluates the health and economic consequences of postponing this critical first dose in the United States.

Modeling the Impact of Vaccination Timing

Universal administration of the hepatitis B vaccine at birth serves as a cornerstone for viral elimination efforts in the United States. However, in 2025, the Advisory Committee on Immunization Practices recommended delaying vaccine initiation among infants born to parents who tested negative for hepatitis B surface antigen (HBsAg, a viral protein indicating active infection). To evaluate the health and economic impact of this policy shift, researchers utilized a Markov model (a statistical simulation that predicts how patients transition between different health states over time). This analysis followed a cohort of 3,628,934 infants born in 2025, tracking their outcomes from birth through age 18 years. The researchers incorporated several critical clinical variables into the simulation, including the prevalence of HBsAg among birthing parents and the rates of maternal testing during pregnancy or delivery. The model accounted for multiple routes of viral acquisition, specifically vertical transmission during birth and horizontal transmission within households or communities. Furthermore, the simulation tracked the long-term sequelae of chronic infection, measuring associated lifetime hepatitis B-related morbidity and mortality to provide a comprehensive view of patient outcomes beyond the acute phase. The study tested eight distinct scenarios where the first vaccine dose was delayed at intervals ranging from 2 months to 12 years. These delays were applied either exclusively to infants of parents who tested negative for HBsAg, or to a broader group including parents with an unknown infection status. All delayed vaccination scenarios were compared against the standard practice of administering the first dose at birth. To ensure clinical realism, the scenarios were modeled under conditions of both perfect and imperfect adherence to vaccination recommendations, with all health care costs calculated using 2025 US dollars.

Quantifying Morbidity and Mortality Risks

The researchers found that all delayed vaccination scenarios resulted in more infections, worse health outcomes, and higher costs compared to standard administration at birth. Even under conditions of perfect adherence, delaying the hepatitis B vaccine by just 2 months for infants born to HBsAg-negative parents led to an additional 90 acute infections (range, 16 to 107). This 2-month delay also resulted in 76 additional chronic infections (range, 14 to 97) and 29 additional hepatitis B-related deaths (range, 6 to 53) within the modeled cohort. For practicing pediatricians and family physicians, these findings suggest that even a brief deviation from the birth-dose schedule introduces measurable clinical risk, potentially exposing infants to horizontal transmission from undiagnosed household contacts. The clinical burden increased significantly as the delay interval lengthened. For instance, postponing the first dose until age 12 years resulted in an additional 190 acute infections (range, 61 to 233) and 50 additional deaths (range, 15 to 83). The model further demonstrated that clinical outcomes worsened when real-world variables were introduced. Specifically, delaying vaccination among infants of parents with unknown HBsAg status amplified all negative outcomes, as did imperfect adherence to the vaccination schedule. These data indicate that the birth dose serves as a critical safety net. In clinical practice, administering the vaccine immediately after birth ensures baseline protection before potential community exposure occurs, which is especially vital when parental infection status is ambiguous or when outpatient follow-up care might be inconsistent.

Economic Consequences of Delayed Prophylaxis

The economic evaluation demonstrated that the clinical risks associated with immunization delays translate directly into substantial financial burdens for the healthcare system. For the cohort of 3,628,934 infants born during a single year, the researchers found that a 2-month delay in the first hepatitis B vaccine dose added $16.4 million in costs. These expenditures stem from the increased medical management of acute and chronic infections, alongside the costly long-term sequelae of the virus, such as cirrhosis and hepatocellular carcinoma. Notably, this figure represents the added financial burden even under the optimistic assumption of perfect adherence to the delayed schedule for infants born to HBsAg-negative parents. The financial impact scaled predictably with the length of the delay, reflecting the cumulative risk of infection and subsequent morbidity. Delaying the first dose to 12 years added nearly $30 million in costs to the healthcare system for a single birth-year cohort. These findings underscore that the birth dose is not merely a preventive clinical measure, but also a highly effective strategy for systemic cost containment. For practicing physicians and hospital administrators, these data reinforce the value of immediate postnatal prophylaxis. Adhering to the birth-dose schedule provides a clear dual benefit: it maximizes individual patient protection during a highly vulnerable developmental window and mitigates the significant economic strain associated with treating entirely preventable viral infections.

References

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA A Cancer Journal for Clinicians. 2005. doi:10.3322/canjclin.55.2.74

2. Badell ML, Prabhu M, Dionne J, Tita ATN, Silverman NS. Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in pregnancy: updated guidelines.. American journal of obstetrics and gynecology. 2024. doi:10.1016/j.ajog.2023.12.023

3. Yao N, Fu S, Wu Y, et al. Incidence of mother-to-child transmission of hepatitis B in relation to maternal peripartum antiviral prophylaxis: A systematic review and meta-analysis.. Acta obstetricia et gynecologica Scandinavica. 2022. doi:10.1111/aogs.14448

4. Tall H, Adam P, Tiendrebeogo ASE, et al. Impact of Introducing Hepatitis B Birth Dose Vaccines into the Infant Immunization Program in Burkina Faso: Study Protocol for a Stepped Wedge Cluster Randomized Trial (NéoVac Study).. Vaccines. 2021. doi:10.3390/vaccines9060583

5. Hefele L, Nouanthong P, Huebschen J, Muller C, Black A. Hepatitis B virus infection in the Lao PDR: A systematic review. medRxiv. 2022. doi:10.1101/2022.01.23.21265872